Antiplatelet and Anticoagulation Therapies

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, international normalized ratio (INR) testing, oral anticoagulants, IV administered drugs such as Heprin, and dual antiplatelet therapy (DAPT). The most commonly used anticoagulant is warfarin, which available in generic form at a low cost. However, it has a narrow therapeutic window and its effectiveness is altered by food containing vitamin K. To regulate warfarin, regular INR testing is needed. The newer anticoagulation drugs are referred to as novel oral anticoagulant (NOAC). However, since some of these drugs are now more than six years old, they are commonly referred to as non-vitamin K oral anticoagulant (NOAC), and the newest term, direct oral anticoagulant (DOAC). NOAC or DOAC agents have much larger therapeutic windows, do not require INR testing. Aspirin and clopidogrel (Plavix) are the most commonly used antiplatelet agents for the prevention of heart attacks and stroke. They are often prescribed together as DAPT.

Resolute Onyx Drug-Eluting Stent Noninferior to Polymer-Free Drug-Coated Stent With One-Month DAPT
News | Stents Drug Eluting | September 30, 2019
September 30, 2019 – The first randomized trial to compare a durable polymer drug-eluting stent to a polymer-free drug-...
Biodegradable Polymer Stent Plus Shortened DAPT Safe and Effective in Unprotected Left Main CAD
News | Stents Drug Eluting | September 30, 2019
September 30, 2019 — A biodegradable polymer everolimus-eluting stent (BP-EES) followed by four months of dual...
Three-Month DAPT Post-PCI Demonstrates Low Adverse Event Rate in High-Bleeding Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 30, 2019
September 30, 2019 – Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy (...
Brilinta Monotherapy Reduces Clinically Relevant Bleeding Risk Post-PCI in High-Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 26, 2019
September 26, 2019 — New data from the Phase IV independent TWILIGHT trial showed Brilinta (ticagrelor) monotherapy...
Aspirin Should Not Be Recommended for Healthy People Over 70
News | Antiplatelet and Anticoagulation Therapies | September 20, 2019
September 20, 2019 — Low-dose aspirin does not prolong disability-free survival of healthy people over 70, even in...
Ticagrelor Plus Aspirin Reduces Ischemic Events in Stable Coronary Patients With Diabetes
News | Antiplatelet and Anticoagulation Therapies | September 10, 2019
September 10,2019 — The combination of ticagrelor and aspirin reduces ischemic events compared with aspirin alone in...
Prasugrel Cuts Ischemic Events in Acute Coronary Syndrome Patients
News | Antiplatelet and Anticoagulation Therapies | September 09, 2019
September 9, 2019 — Prasugrel is superior to ticagrelor for reducing ischemic events in patients with acute coronary...
PAD Intervention Patients on Statins Less Likely to Face Amputation
News | Peripheral Artery Disease (PAD) | August 23, 2019
August 23, 2019 – Patients with peripheral artery disease (PAD) were significantly less likely to face amputation after...
Statins Reduce Stroke, Cardiovascular Risk in Cancer Patients Following Radiation
News | Cardio-oncology | July 29, 2019
July 29, 2019 — Cancer patients taking cholesterol-lowering statin medication following radiation therapy of the chest...
Advances in Anticoagulants Expand Options for VTE Prevention, Treatment
News | Antiplatelet and Anticoagulation Therapies | July 26, 2019
July 26, 2019 — A new article published in AACN Advanced Critical Care outlines the traditional anticoagulant therapies...
Videos | Atrial Fibrillation | June 21, 2019
Sanjaya Gupta, M.D., electrophysiologist, St. Luke's Mid America Heart Institute, and assistant professor, University...
Global Afib Patient Registry Shows New Tools Needed to Assess Patient Risk
News | Patient Engagement | June 17, 2019
June 17, 2019 – Initial results from the AVIATOR 2 international registry were presented as late-breaking clinical...
Boston Scientific Initiates OPTION Trial of Watchman FLX
News | Left Atrial Appendage (LAA) Occluders | June 12, 2019
June 12, 2019 — Boston Scientific Corp. has initiated the OPTION trial to compare safety and effectiveness of the next-...
Fragmin (dalteparin sodium) injection was cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Fragmin (dalteparin sodium) injection is now cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Technology | Antiplatelet and Anticoagulation Therapies | May 17, 2019
May 17, 2019 — The U.S. Food and Drug Administration (FDA) this week approved Fragmin (dalteparin sodium) injection,...
PhaseBio Receives FDA Breakthrough Therapy Designation for Ticagrelor Reversal Agent
Technology | Antiplatelet and Anticoagulation Therapies | April 30, 2019
April 30, 2019 — PhaseBio Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has granted...